Erratum to: Rheumatol Int DOI 10.1007/s00296-014-3047-6
Unfortunately, the probability values in the section “Chemokine and cytokine results” was incorrect in the published article.
The correct section should read as follows:
There was a significant decrease between the initial and final serum levels in interleukin-1α (IL), IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17α, interferon (IFN), tumor necrosis factor alpha (TNF-α), and granulocyte macrophage colony-stimulating factor (GM-CSF) in the oral GAGs group (P < 0.05). The placebo group had significant increases in IL-1α, IL-1β, IL-2, IL-4, IL-6, and TNF-α (P < 0.05). There was also a significant decrease between the initial and final SF levels in most chemokines and cytokines in the oral GAGs group (P < 0.05), whereas the placebo group had significant increases in IL-10, IFN, TNF-α, and GM-CSF (P < 0.05). Overall, the oral preparation had decreased serum and synovial cytokine levels while patients on placebo had increased levels over the same 12 weeks.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00296-014-3047-6.
Rights and permissions
About this article
Cite this article
Nelson, F.R., Zvirbulis, R.A., Zonca, B. et al. Erratum to: The effects of an oral preparation containing hyaluronic acid (Oralvisc®) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analyses. Rheumatol Int 35, 53 (2015). https://doi.org/10.1007/s00296-014-3078-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-3078-z